Learn more about Engitix

Engitix announces the appointment of two biotech industry leaders as Scientific Advisors: Adrian S. Ray, PhD, and Scott Turner, PhD

Engitix Ltd (‘Engitix’), today announces the appointment of Matthew Edwards, Ph.D., as Senior Vice President of Discovery Sciences, and Emma Huang, Ph.D., as Vice President

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix (ECM) platform, today announces the appointment of Christopher (Chris) Stevenson, Ph.D. as Chief Scientific Officer (CSO).

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director.

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today celebrated its expansion and growth with a Grand Opening at its new facilities in White City, West London.

Biopharma Dealmakers – Nature – View full story

Nature Biotechnology – View full story

Genetic Engineering & Biotechnology News – View full story

BioWorld – View full story (behind a paywall)

Bloomberg – View full story

Fierce Biotech – View full story

Pharmaceutical Technology – View full story

Endpoints – View full story

Collaboration and Licensing agreement to develop new anti-fibrotic therapies in inflammatory bowel disease (IBD)

Labiotech – View full story

Endpoints News – View full story

Bloomberg – View full story

Pharmafile – View full story

Labiotech.eu – View full story

LaingBuisson – View full story

SCRIP – View full story (behind a paywall)

BioWorld – View full story (behind a paywall)

Collaboration and Investment agreement to accelerate the clinical translation of fibrosis and solid tumours targets and discovery of precision engineered medicines.

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology.

The company is on expansion curve with two new appointments and recent move to larger facilities – 23 Feb, 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform.

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP).

Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix (ECM) platform, today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors.

Pharmaceutical Technology – View full story

SCRIP – View full story (behind a paywall)

Endpoints News – View full story

BioWorld – View full story (behind a paywall)

Licensing and Collaboration agreement to discover and develop novel therapeutics for advanced fibrotic liver diseases.

Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, and Morphic Therapeutic (‘Morphic’), a biopharmaceutical company developing oral integrin therapies, today announce that they have entered into a research collaboration

Bloomberg – View full story

Golden Ticket includes one year of lab bench space at Cambridge, MA-based shared laboratory and office space London, UK, 5 November 2019 – Engitix Ltd (‘Engitix’), a private company focused on drug discovery for fibrosis and solid tumours based on its pioneering human extracellular matrix (ECM) platform, announced that its subsidiary Engitix, Inc, has been awarded a Golden Ticket

Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces the appointment of Gino Van Heeke, PhD, as Chief Scientific Officer (CSO), effective 7th May.

27 November 2018 – Engitix Ltd, a company pioneering the development of both tissue-specific and disease-specific human extracellular matrix (ECM) for accelerating and improving the drug discovery process, today announces it has closed a £5 million Series A financing, led by a private investor.